Last updated 18 days ago
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
360 patients around the world
Available in Puerto Rico, Spain, Colombia, United States, Mexico, Argentina, Brazil
Bristol-Myers Squibb
17Research sites
360Patients around the world
This study is for people with
Myelodysplastic Syndromes
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participant has documented diagnosis of MDS according to World Health Organization (WHO) 2016 that meet IPSS-R classification of very low, low, or intermediate-risk disease, (intermediate-risk of ≤ 3.5 IPSS-R score) confirmed via bone marrow aspirate and: i) < 5% blasts in bone marrow and < 1% blasts in peripheral blood.Participant is not transfusion dependent (NTD) based on IWG2018 criteriaParticipant has never received treatment with an erythropoiesis stimulating agent (ESA)Participant has a baseline endogenous serum erythropoietin (sEPO) level of ≤ 500 U/L.Participant has symptoms of anemia: i) Participant records a severity score of "moderate" or greater on at least 1 PGI-S item of fatigue, weakness, shortness of breath, or dizziness performed during the screening period.Participant has a mean baseline Hb concentration prior to randomization of ≤ 9.5 g/dL. Mean Hb is defined as the mean of all central/ local/ pretransfusion available Hb measurements during the 16 weeks prior to randomization (with a minimum of 2 measurements at least 1 week apart). Only Hb levels > 21 days following a transfusion are acceptable. The last measurement must be within 35 days of randomization.
- Participant with secondary MDS (that is, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases).Participant with known history of diagnosis of AML.Participant with history of cerebrovascular accident (including ischemic, embolic, and hemorrhagic cerebrovascular accident), transient ischemic attack, deep venous thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to randomization.Participant with a history of pure red cell aplasia and/or antibody against erythropoietin.
Sites
Hospital Británico de Buenos Aires - CABA
Recruiting
Swiss Medical Center Barrio Parque - CABA
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul
Recruiting
HEMORIO Instituto Nacional de Hematología
Recruiting
Hospital das Clínicas da FMUSP - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP
Recruiting
Hospital Universitário Walter Cantídio - Universidade Federal do Ceará - Fortaleza, Ceara
Recruiting
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Instituto Oncológico FALP (Fundación Arturo Lopez Perez)
Recruiting
Inmunocel
Recruiting
StudyELEMENT-MDS
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Myelodysplastic Syndromes
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05949684
